Table 1.
Patients baseline and therapy-related characteristics.
Patient | Age | Diagnosis | Donor Type | GVHD before relapse | Time from transplant to relapse | Therapy after relapse | Blasts in BM before CAR-T Therapy (%) | Blasts in PB before CAR-T Therapy (%) | Donor chimerism (BM) (%) | Time from relapse to CAR-T therapy | Time from stop immuno-suppressive therapy to CAR-T therapy |
---|---|---|---|---|---|---|---|---|---|---|---|
Pt1# | 41–45 | B-ALL (Ph+) | MMUDT (8/10) | Grade I aGVHD, cGVHD | 58 months | TKI | 60.4 | 36.5 | 8.82 | 0.5 months | 51 months |
Pt 2# | 46–50 | B- ALL | MSDT | Grade II aGVHD, cGVHD | 18 months | No | 26.2 | 16.4 | 20.55 | 0.5 months | 7 months |
Pt 3# | 56–60 | B-ALL | Haplo-HSCT (7/10) | Grade I aGVHD | 11 months | No | 5.6 | 2.6 | 79.12 | 1 months | 9 months |
Pt 4# | 31–35 | B-ALL | Haplo-HSCT (5/10) | No | 5 months | No | 68.8 | 46.5 | 39.35 | 0.5 months | 3 months |
Pt 5# | 21–25 | B-ALL | Haplo-HSCT (5/10) | Grade I aGVHD, cGVHD | 15 months | No | 45.2 | 22.9 | 48.36 | 0.5 months | 6 months |
Pt 6# | 16–20 | B-ALL | MUDT | Grade II aGVHD | 4 months | Two courses | 58.4 | 39.4 | 23.12 | 2 months | 3 months |
Pt 7# | 11–15 | B-ALL (Ph+) | Haplo-HSCT (5/10) | No | 6 months | No | 16.2 | 8.6 | 83.02 | 1 months | 5 months |
Pt 8# | 11–15 | B-ALL | MSDT | Grade I aGVHD | 14 months | One course | 32.8 | 16.8 | 77.13 | 1 months | 9 months |
Pt 9# | 21–25 | B-ALL (Ph+) | Haplo-HSCT (5/10) | No | 13 months | TKI | 48.6 | 33.5 | 36.18 | 0.5 months | 11 months |
Pt 10# | 56–60 | B-ALL | MSDT | Grade I aGVHD | 9 months | Two courses | 52.4 | 50.4 | 52.08 | 3 months | 4 months |
Pt 11# | 21–25 | B-ALL | MSDT | No | 24 months | No | 40.8 | 29.8 | 50.25 | 0.5 months | 20 months |
Pt 12# | 16–20 | B-ALL (Ph+) | Haplo-HSCT (5/10) | Grade I aGVHD | 9 months | TKI | 82.0 | 66.8 | 29.14 | 1 months | 4 months |
Pt 13# | 21–25 | B-ALL | Haplo-HSCT (5/10) | Grade II aGVHD | 15 months | Three courses | 12.8 | 8.8 | 85.16 | 6 months | 6 months |
Pt 14# | 16–20 | B-ALL | Haplo-HSCT (5/10) | Grade II aGVHD | 7 months | No | 40.2 | 25.5 | 56.75 | 0.5 months | 3 months |
Pt 15# | 11–15 | B-ALL | Haplo-HSCT (5/10) | Grade I aGVHD | 5 months | No | 65.5 | 45.6 | 42.47 | 0.5 months | 0.5 months |
HLA-matched sibling donor transplantation, MSDT; HLA-matched unrelated donor transplantation, MUDT; HLA-mismatched unrelated donor transplantation, MMUDT; Haploid donor transplantation, Haplo-HSCT; Tyrosine kinase inhibitor, TKI.
Chemotherapy after relapse: Pt 6# Two courses of VDCP. Pt 8# One course of VCP. Pt 10# One course of FLAG and one course of VDCP.
Pt 13# Two courses of Hyper-CVAD and one course of FLAG.